End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
18.16
CNY
|
-5.42%
|
|
+7.01%
|
-10.76%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
7,099
|
4,167
|
5,761
|
6,479
|
7,772
|
5,859
|
Enterprise Value (EV)
1 |
9,498
|
6,440
|
8,044
|
9,989
|
12,421
|
11,591
|
P/E ratio
|
32.2
x
|
16
x
|
18.8
x
|
19.6
x
|
21
x
|
14.4
x
|
Yield
|
0.62%
|
1.32%
|
-
|
1.02%
|
-
|
1.48%
|
Capitalization / Revenue
|
1.64
x
|
0.7
x
|
0.82
x
|
0.92
x
|
0.88
x
|
0.56
x
|
EV / Revenue
|
2.2
x
|
1.08
x
|
1.14
x
|
1.41
x
|
1.4
x
|
1.1
x
|
EV / EBITDA
|
15
x
|
6.89
x
|
7.57
x
|
9.73
x
|
10.1
x
|
9.11
x
|
EV / FCF
|
-16
x
|
358
x
|
105
x
|
-9.56
x
|
-21.9
x
|
-11.4
x
|
FCF Yield
|
-6.24%
|
0.28%
|
0.95%
|
-10.5%
|
-4.57%
|
-8.78%
|
Price to Book
|
3.1
x
|
1.66
x
|
2.09
x
|
2.02
x
|
2.24
x
|
1.51
x
|
Nbr of stocks (in thousands)
|
579,534
|
579,534
|
579,534
|
579,534
|
579,538
|
579,543
|
Reference price
2 |
12.25
|
7.190
|
9.940
|
11.18
|
13.41
|
10.11
|
Announcement Date
|
3/28/18
|
4/23/19
|
4/29/20
|
4/26/21
|
4/26/22
|
4/25/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
4,319
|
5,964
|
7,052
|
7,069
|
8,860
|
10,494
|
EBITDA
1 |
634.6
|
935.3
|
1,062
|
1,026
|
1,227
|
1,272
|
EBIT
1 |
487.2
|
733.1
|
831.4
|
735
|
949.2
|
978.5
|
Operating Margin
|
11.28%
|
12.29%
|
11.79%
|
10.4%
|
10.71%
|
9.32%
|
Earnings before Tax (EBT)
1 |
386.7
|
591.9
|
685.7
|
635.8
|
780.5
|
819.7
|
Net income
1 |
219.2
|
262
|
309.5
|
330
|
380.2
|
417.7
|
Net margin
|
5.08%
|
4.39%
|
4.39%
|
4.67%
|
4.29%
|
3.98%
|
EPS
2 |
0.3800
|
0.4500
|
0.5300
|
0.5700
|
0.6400
|
0.7000
|
Free Cash Flow
1 |
-592.7
|
17.97
|
76.32
|
-1,045
|
-567.6
|
-1,018
|
FCF margin
|
-13.72%
|
0.3%
|
1.08%
|
-14.79%
|
-6.41%
|
-9.7%
|
FCF Conversion (EBITDA)
|
-
|
1.92%
|
7.18%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
6.86%
|
24.66%
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0760
|
0.0950
|
-
|
0.1140
|
-
|
0.1500
|
Announcement Date
|
3/28/18
|
4/23/19
|
4/29/20
|
4/26/21
|
4/26/22
|
4/25/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
2,399
|
2,273
|
2,284
|
3,510
|
4,649
|
5,732
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.78
x
|
2.431
x
|
2.15
x
|
3.42
x
|
3.788
x
|
4.507
x
|
Free Cash Flow
1 |
-593
|
18
|
76.3
|
-1,045
|
-568
|
-1,018
|
ROE (net income / shareholders' equity)
|
12%
|
14.7%
|
15.4%
|
13.3%
|
14.1%
|
13.9%
|
ROA (Net income/ Total Assets)
|
5.42%
|
6.25%
|
6.27%
|
4.78%
|
5.35%
|
4.61%
|
Assets
1 |
4,043
|
4,193
|
4,937
|
6,899
|
7,112
|
9,063
|
Book Value Per Share
2 |
3.950
|
4.320
|
4.760
|
5.530
|
5.970
|
6.710
|
Cash Flow per Share
2 |
0.9500
|
0.6400
|
1.460
|
1.440
|
1.770
|
1.740
|
Capex
1 |
346
|
264
|
289
|
332
|
301
|
272
|
Capex / Sales
|
8.02%
|
4.43%
|
4.09%
|
4.7%
|
3.4%
|
2.59%
|
Announcement Date
|
3/28/18
|
4/23/19
|
4/29/20
|
4/26/21
|
4/26/22
|
4/25/23
|
|
1st Jan change
|
Capi.
|
---|
| -10.76% | 1.5B | | -9.59% | 7.67B | | -1.20% | 5.26B | | +26.10% | 5.36B | | +0.02% | 4.57B | | -53.02% | 3.15B | | +6.42% | 2.59B | | -14.95% | 2.06B | | -8.29% | 1.79B | | +0.42% | 1.74B |
Diagnostic & Testing Substances
|